Dangerous Drug News

Side Effect Information About Dangerous Drugs and Medical Devices

Altrumedia
  • Home
  • About
  • Dangerous Drug News
  • Drugs
    • Fluoroquinolone Antibiotics
    • Pradaxa
    • Proton Pump Inhibitors
    • Risperdal
    • Talcum Powder
    • Taxotere
    • Xarelto
    • Zofran
  • Medical Devices
    • Essure
    • IVC Filters
    • Power Morcellators
    • Transvaginal Mesh
  • Free Case Evaluation

Transvaginal Mesh

17100210_l

Transvaginal mesh is a medical device used to treat stress urinary incontinence (SUI) and pelvic organ prolapse (POP) in women. It was initially seen as an improvement over traditional surgery to treat the conditions, because the procedure to place it is minimally invasive and requires a smaller incision. Over time it was discovered that serious transvaginal mesh complications were not uncommon and they can be irreversible.

What is Transvaginal Mesh?

Transvaginal mesh is surgical mesh that is inserted in a woman’s body, transvaginally, to treat SUI and POP. It is sometimes referred to as a bladder sling. The mesh is used to support internal organs when the pelvic floor has become weak as a result of childbirth, obesity or another cause.

In transvaginal placement, the mesh is inserted through an incision in the vaginal wall. The mesh can be placed abdominally instead. The transvaginal procedure was thought to be an improvement because it is less invasive.

Pelvic Floor Disorders

SUI is a condition in which the muscles that support the bladder or urethra are weak, causing women to experience urine leakage, sometimes from very minor activity such as sneezing or laughing. In POP, the tissues that hold the pelvic organs in place are weak or stretched, allowing one or more of the organs, such as the bladder or small bowel, to protrude into the vagina.

Both conditions can sometimes be treated with surgery that does not involve any surgical mesh.

Transvaginal Mesh Injuries

Transvaginal mesh complications can include:

  • Erosion of the mesh into the vagina
  • Vaginal scarring
  • Vaginal shrinkage, due to scar tissue
  • Infection
  • Bleeding
  • Pelvic pain
  • Vaginal fistulas
  • Organ perforation
  • Severe pain during intercourse
  • Neuromuscular problems
  • Emotional problems
  • Recurrence of POP or SUI

Treatment for transvaginal mesh complications includes surgery to remove the mesh, often multiple surgeries. However, it is not always possible to completely remove the mesh because it is designed to be permanent and, over time it becomes integrated with the body’s tissues. Transvaginal mesh injuries can be permanent. The longer the mesh is in place, the more difficult it is to remove.

The FDA and Transvaginal Mesh

In 2008, the U.S. Food and Drug Administration (FDA) said that transvaginal mesh complications were rare. In 2011, it revised its stance, stating that complications were not rare. Later that year it convened and advisory panel to gather recommendations on transvaginal mesh for POP.

In 2012, the FDA issued post market study orders to numerous manufacturers of transvaginal mesh for POP and SUI repair. And in January 2016, the agency gave manufacturers of existing transvaginal mesh for POP 30 months submit a premarket approval (PMA) to address safety concerns.

If you have concerns about transvaginal mesh or believe you have been harmed, email us now for a free case evaluation.  We will help you find answers to your questions and we can help you find an attorney who represents victims injured by transvaginal mesh.

Share this:

  • Facebook
  • LinkedIn
  • Twitter

RSS FDA Med Watch

  • 2023 Safety Communications
  • Evaluation of Safety Concerns with Certain Dental Devices Used on Adults – FDA Safety Communication
  • Jarman’s Midwest Cleaning Systems, Inc. Issues Voluntary Nationwide Recall of Alcohol Antiseptic 80% Topical Solution Hand Sanitizer Non-sterile Solution and Isopropyl Alcohol Antiseptic 75% Topical Solution Hand Sanitizer Non-sterile Solution Due to Presence of Methanol
  • Risks with Exactech Joint Replacement Devices with Defective Packaging – FDA Safety Communication
  • Ascend Laboratories LLC. Issues Voluntary Nationwide Recall of Dabigatran Etexilate Capsules, USP 75 mg and 150 mg, Due to the Detection of N-Nitroso-dabigatran (NDAB) Impurity
  • UPDATE: Reports of Squamous Cell Carcinoma (SCC) in the Capsule Around Breast Implants - FDA Safety Communication
  • 2023 Medical Device Recalls

Recent Headlines

Diabetic Man Testing Blood Levels

Type 2 Diabetes Drugs Pose Numerous Health Risks

The hits just keep coming for Johnson & Johnson, and now its … [Read More...]

PPIs Side Effects

PPI Heartburn and Ulcer Medications May Cause Stomach Cancer

Proton pump inhibitors (PPIs) are used to treat heartburn, … [Read More...]

Johnson & Johnson Loses Second Major Talcum Powder Case

In its second trial loss in less than 3 months, Johnson & … [Read More...]

Find an Attorney

RSS US Recall News

  • Belviq Withdrawn Due to Cancer Risk
  • Common Heartburn Medication may lead to bladder, stomach, and other cancers. Zantac Lawsuits begin.
  • J&J Settles Talc Mesothelioma Settlement

RSS Lawsuits and Settlements

  • Possible Lawsuit: CPAP Lung Cancer Lawsuit News and Legal Information
  • Possible Lawsuit: Birth Injury and Birth Defect Lawsuit News and Legal Information
  • Possible Lawsuit: Wyoming Medical Malpractice Lawsuit News & Legal Information

RSS Mass Tort News

RSS Health Industry

  • BREAKING: Gwyneth Paltrow Cleared In $3M Ski Crash Trial
  • Ex-CEO Whistleblower Nets $12M In Hospital's $69M FCA Deal
  • BREAKING: Trump Charged In Sealed NY Indictment

ABOUT US

DRUG INFO

DEVICES

CASE REVIEW

NEWS

Copyright © 2023 DangerousDrugNews.com · Site Map - Website Development by Altrumedia · Log in